Lv57
920 积分 2024-07-24 加入
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial
12天前
已关闭
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
13天前
已完结
Does OptiTROP-Lung05 open a new frontier for first-line ADC-ICI combinations in NSCLC?
15天前
已完结
Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)
15天前
已完结
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
16天前
已完结
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management
16天前
已完结
The next generation of antibody–drug conjugates
16天前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
1个月前
已完结
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
